Glenmark receives FDA approval for cardiac drug Multaq

Multaq tablets had sales of $425 min in US in past twelve months

Glenmark has received tentative approval from the US Food and Drugs Administration for generic version of Multaq tablets. The tablets are indicated for persons suffering from irregular heart beats. Tentative approval means the drug has met all safety and quality standards but can not be distributed because of existing patent protection or exclusivities.

According to IMS data Multaq tablets had sales of $425 million in US in past twelve months.